Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

Published:2016-11-28 Issue:1 Volume:16 Page:5-12
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Haguet Hélène¹²,Douxfils Jonathan¹,Mullier François²,Chatelain Christian¹,Graux Carlos³,Dogné Jean-Michel¹

Affiliation:

1. Department of Pharmacy, University of Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium

2. Haematology Laboratory, Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium

3. Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2017.1261824

Reference26 articles.

1. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

2. Australian Government. Australian public assessment report for Iclusig. 2015. [cited 2016 Nov 3]. Available from: https://www.tga.gov.au/sites/default/files/auspar-ponatinib-150416.docx

3. Epidemiology of chronic myeloid leukaemia: an update

4. Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System

5. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies;Current Treatment Options in Oncology;2024-06-12

2. Cancer-associated thrombosis in hematologic malignancies;International Journal of Hematology;2024-01-25

3. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors;PLOS ONE;2023-11-20

4. Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases;Acta Neurochirurgica;2023-11-06

5. Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management;European Journal of Haematology;2023-04-25